Skip to main content
Premium Trial:

Request an Annual Quote

Alpha Innotech, GE, Guava Technologies, Fisher Scientific, Molecular Devices, Boehringer Ingelheim, Evotec, Galapagos


Alpha Innotech Partners with GE to Bundle Software with NovaRay Reader

Alpha Innotech is partnering with GE Healthcare to bundle its NovaRay multiplex array reader with the ArrayVision microarray analysis software, the companies said this week.

Alpha Innotech is marketing NovaRay as an "all-in-one" reader that can also be applied to high-content cell-based screens (see CBA News, 9/21/2004).

Further details of the deal were not disclosed.

GE Healthcare Q4 Revenues Up 5.4 Percent

General Electric this week reported that revenues for its healthcare segment increased by 5.4 percent for the fourth quarter of 2005, to $4.49 billion from $4.26 billion during the fourth quarter of 2004.

GE reported total earnings of $18.3 billion for 2005, up 12 percent from $16.3 billion in 2004. Earnings per share were $1.72, up 10 percent from 2004.

The company did not disclose its research and development spending for the fourth quarter of 2005.

Guava Technologies Secures $10M Debt Financing from Hercules

Guava Technologies has closed a $5.5-million secured debt financing and an additional one-year credit line of $4.5 million from Palo-Alto based specialty finance provider Hercules Technology, Guava said this week.

Guava will use $4 million of the financing to retire previous debt, the company said in a statement.

CEO Larry Bruder said the remaining $6 million line of credit will be useful to the company "as we continue to accelerate revenue growth through new product development programs such as our new EasyCyte Mini and the Guava Express reagent line."

In November, Guava raised $7 million in private equity and forecasted positive cash flows "within 12 months." (See CBA News, 12/5/2005)

Fisher Scientific, Molecular Devices Schedule Earnings Releases

Fisher Scientific said this week that it will release its fourth-quarter financial results on Tuesday, Feb. 7, after the close of market trading.

Fisher will host a conference call to discuss the financial results on Wednesday, Feb. 8, at 10 am Eastern time. A replay of the call will be available for two weeks.

Molecular Devices has also scheduled its fourth-quarter earnings release for Feb. 7, after the close of market trading.

Senior management will hold a conference call on Wednesday, Feb. 8, at 11 am Eastern time to discuss operating results and other business matters, MDCC said.

Boehringer Ingelheim Expands Drug Discovery Collaboration with Evotec…

Evotec said this week that it has expanded its drug discovery collaboration with Boehringer Ingelheim initiated in September 2004, effectively doubling the size of the existing program.

Additionally, Evotec said that the collaboration was originally scheduled to end in August 2007, but will now be extended to the end of 2008.

The original contract was exclusively targeted at therapeutics acting on G-Protein Coupled Receptors. The extension includes targets from different classes, including ion channels and enzymes, Evotec said.

Evotec will receive ongoing research payments from Boehringer, as well as pre-clinical and clinical milestones, and royalties on drugs discovered.

… and Pens Target-Discovery Deal with Galapagos

Galapagos said this week that its BioFocus service division will use its siRNA-based gene collection to provide Boehringer Ingelheim with novel drug targets.

The three-year deal could be worth more than €2 million ($2.4 million), Galapagos said.

Terms of the collaboration call for BioFocus to expand its SilenceSelect siRNA-based gene collection with an additional gene set, develop a dedicated cellular assay in the field of autoimmune disease, and use this assay to run a target-discovery screen, the company said.

Galapagos will receive upfront fees, as well as research and development funding, and stands to receive milestone fees when certain drug-discovery criteria are met.

Additional terms were not provided.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more